GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Ending Cash Position

Equillium (FRA:0FY) Ending Cash Position : €21.29 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Ending Cash Position?

Equillium's Ending Cash Position for the quarter that ended in Dec. 2023 was €21.29 Mil.

Equillium's quarterly Ending Cash Position increased from Jun. 2023 (€23.65 Mil) to Sep. 2023 (€32.22 Mil) but then declined from Sep. 2023 (€32.22 Mil) to Dec. 2023 (€21.29 Mil).

Equillium's annual Ending Cash Position increased from Dec. 2021 (€44.57 Mil) to Dec. 2022 (€55.80 Mil) but then declined from Dec. 2022 (€55.80 Mil) to Dec. 2023 (€21.29 Mil).


Equillium Ending Cash Position Historical Data

The historical data trend for Equillium's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Ending Cash Position Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 11.90 19.71 44.57 55.80 21.29

Equillium Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.80 22.89 23.65 32.22 21.29

Equillium Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Equillium's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=54.201+-32.912
=21.29

Equillium's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=31.529+-10.24
=21.29


Equillium Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Equillium's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium (FRA:0FY) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines